Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Boston Scientific releases results from Taxus OLYMPIA registry

Boston Scientific : 15 October, 2008  (Company News)
Boston Scientific has announced positive one-year results from the Intercontinental and European launch phases of its global Taxus OLYMPIA registry, the world's largest prospective, post-approval registry for a single drug-eluting stent (DES).
OLYMPIA is designed to analyse real-world clinical outcomes data for Boston Scientific's second-generation Taxus Liberte Paclitaxel-Eluting Coronary Stent System in the treatment of patients with coronary artery disease. Outcomes from the 22,000-patient study focused on high-risk lesion subgroups and patients with serious co-morbid conditions.

The results were presented by Waqar H Ahmed, MD, at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, DC, USA.

The Taxus OLYMPIA registry employs a consecutive enrollment process and consists of diverse and high-risk patient populations, reflecting real-world patients found in everyday clinical practice. One-year data were collected for a total of 22,345 patients to date in 57 countries with cardiac events validated by independent medical review. A large majority of patients (75 percent) were considered 'expanded use' cases consisting of challenging lesions or complex clinical characteristics. The overall OLYMPIA population included patients with multivessel disease (56.5 percent), prior PCI (27.9 percent), multiple stents (32.3 percent), and medically treated diabetes (27.0 percent).

One-year data demonstrated excellent outcomes for the Taxus Liberte Stent in patients with high-risk lesions (small vessels, long lesions, B2/C lesions) and patients with co-morbid conditions (prior stroke, acute MI, chronic renal disease). Results demonstrated a low overall 4.4 percent rate of Taxus Liberte stent-related composite cardiac events, including cardiac death (1.4 percent), MI (0.9 percent), and re-intervention (TVR) (3.1 percent). The definite Stent thrombosis rate was 0.8 percent after one year. The Taxus Liberte Stent also exhibited a high degree of procedural success at 99.7 percent.

'The OLYMPIA registry continues to show impressive safety and efficacy data for the Taxus Liberte Stent in the largest, prospective DES patient population ever studied for an individual stent,' said Dr Ahmed, Armed Forces Hospital, Jeddah, Saudi Arabia. 'The low occurrence of cardiac events and Stent thrombosis is noteworthy, especially given the large percentage of high-risk patients and lesions from real-world practice in this study.'

In the medically treated diabetic subset of 5,692 patients, OLYMPIA reported a 5.1 percent rate of overall Taxus Liberte stent-related cardiac events, including cardiac death (2.3 percent), MI (1.1 percent), and re-intervention (TVR) (3.1 percent). Definite Stent thrombosis was 0.8 percent, and remained low even in the insulin-treated diabetic patients at 1.0 percent. The diabetic patient subset is typically considered to be at high risk for adverse events associated with bare-metal stenting.

'The one-year OLYMPIA results reinforce the impressive safety and efficacy data seen in the pivotal trial for the Taxus Liberte Stent,' said Donald S Baim, MD, chief medical and scientific officer of Boston Scientific. 'This second-generation platform offers thinner struts for exceptional deliverability and a Stent geometry designed for more uniform drug elution.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo